"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

E. Engelsman, J. C M Klijn, R. D. Rubens, J. Wildiers, L. V A M Beex, M. A. Nooij, N. Rotmensz, R. Sylvester

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

The "classical" CMF (cyclophosphamide/methotrexate/5-fluorouracil) schedule was compared with a modified 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer, as concern had arisen as to whether the classical schedule was the optimal way to give these drugs. The response rate with classical CMF was 48% compared with 29% for intravenous CMF (P = 0.003). Response duration was similar at 11 months, but survival longer for the classical schedule (17 versus 12 months, P = 0.016). We conclude that classical CMF is the superior regimen and attribute this to the higher dose intensity achieved.

Original languageEnglish
Pages (from-to)966-970
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number8
DOIs
Publication statusPublished - 1991

Fingerprint

Methotrexate
Fluorouracil
Cyclophosphamide
Appointments and Schedules
Breast Neoplasms
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). / Engelsman, E.; Klijn, J. C M; Rubens, R. D.; Wildiers, J.; Beex, L. V A M; Nooij, M. A.; Rotmensz, N.; Sylvester, R.

In: European Journal of Cancer and Clinical Oncology, Vol. 27, No. 8, 1991, p. 966-970.

Research output: Contribution to journalArticle

@article{e7bf18d5248b4af2acc1b5b1ce1f67f0,
title = "{"}Classical{"} CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)",
abstract = "The {"}classical{"} CMF (cyclophosphamide/methotrexate/5-fluorouracil) schedule was compared with a modified 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer, as concern had arisen as to whether the classical schedule was the optimal way to give these drugs. The response rate with classical CMF was 48{\%} compared with 29{\%} for intravenous CMF (P = 0.003). Response duration was similar at 11 months, but survival longer for the classical schedule (17 versus 12 months, P = 0.016). We conclude that classical CMF is the superior regimen and attribute this to the higher dose intensity achieved.",
author = "E. Engelsman and Klijn, {J. C M} and Rubens, {R. D.} and J. Wildiers and Beex, {L. V A M} and Nooij, {M. A.} and N. Rotmensz and R. Sylvester",
year = "1991",
doi = "10.1016/0277-5379(91)90259-G",
language = "English",
volume = "27",
pages = "966--970",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "8",

}

TY - JOUR

T1 - "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

AU - Engelsman, E.

AU - Klijn, J. C M

AU - Rubens, R. D.

AU - Wildiers, J.

AU - Beex, L. V A M

AU - Nooij, M. A.

AU - Rotmensz, N.

AU - Sylvester, R.

PY - 1991

Y1 - 1991

N2 - The "classical" CMF (cyclophosphamide/methotrexate/5-fluorouracil) schedule was compared with a modified 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer, as concern had arisen as to whether the classical schedule was the optimal way to give these drugs. The response rate with classical CMF was 48% compared with 29% for intravenous CMF (P = 0.003). Response duration was similar at 11 months, but survival longer for the classical schedule (17 versus 12 months, P = 0.016). We conclude that classical CMF is the superior regimen and attribute this to the higher dose intensity achieved.

AB - The "classical" CMF (cyclophosphamide/methotrexate/5-fluorouracil) schedule was compared with a modified 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer, as concern had arisen as to whether the classical schedule was the optimal way to give these drugs. The response rate with classical CMF was 48% compared with 29% for intravenous CMF (P = 0.003). Response duration was similar at 11 months, but survival longer for the classical schedule (17 versus 12 months, P = 0.016). We conclude that classical CMF is the superior regimen and attribute this to the higher dose intensity achieved.

UR - http://www.scopus.com/inward/record.url?scp=0025743487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025743487&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90259-G

DO - 10.1016/0277-5379(91)90259-G

M3 - Article

C2 - 1832904

AN - SCOPUS:0025743487

VL - 27

SP - 966

EP - 970

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -